

REPORT OF THE BOARD OF TRUSTEES

B of T Report 16-A-24

Subject: Support for Mental Health Courts

Presented by: Willie Underwood, III, MD, MSc, MPH, Chair

Referred to: Reference Committee B

1 INTRODUCTION

2

3 At the 2023 Annual Meeting of the American Medical Association (AMA) House of Delegates  
4 (HOD), Resolution 202 entitled, “Support for Mental Health Courts,” was introduced by the  
5 Medical Student Section and called on the AMA to amend existing policy – Policy H-100.955  
6 entitled, “Support for Drug Courts” – as follows:

7

8 Our AMA: (1) supports the establishment and use of mental health drug courts,  
9 including drug courts and sobriety courts, as an effective method of intervention within  
10 a comprehensive system of community-based supports and services for individuals  
11 with mental illness involved in the justice system ~~addictive disease who are convicted~~  
12 ~~of nonviolent crimes;~~ (2) encourages legislators to establish mental health drug courts  
13 at the state and local level in the United States; and (3) encourages mental health drug  
14 courts to rely upon evidence-based models of care for those who the judge or court  
15 determine would benefit from intervention rather than incarceration.

16

17 There was robust discussion of this resolution, including widespread support for increasing access  
18 to evidence-based care for individuals with a mental illness or substance use disorder (SUD) who  
19 were involved with the justice system. Multiple questions were raised, however, regarding terms  
20 of art that may be in use in legal settings compared to medical settings; the potential of unintended  
21 consequences; and the different uses of such courts. Ultimately, the HOD referred this resolution  
22 to the Board of Trustees for study. In response, this report provides background information;  
23 discusses the different courts; presents AMA policy; and makes recommendations.

24

25 BACKGROUND

26

27 There are more than 4,000 courts in the United States that provide some measure of alternative to  
28 incarceration when there is evidence of a mental illness, SUD, or other health condition impacting  
29 an individual and/or family.<sup>1</sup> There are at least 39 states with a diversion program that addresses  
30 substance use, and at least 24 that directly address mental health and illness needs.<sup>2</sup> A fact sheet  
31 from the Obama Administration noted that, “Since 1989, drug courts have been established or are  
32 being planned in all 50 States, the District of Columbia, the Northern Mariana Islands, Puerto Rico,  
33 Guam, and in nearly 90 Tribal locations.”<sup>3</sup> The AMA has long been a supporter of these programs.<sup>4</sup>

34

35 These programs go by many names, including “treatment court,” “adult drug court,” “DWI court,”  
36 “family treatment court,” “juvenile treatment court,” “tribal healing to wellness court,” or “veterans  
37 treatment court.” Other names used to describe programs that seek alternatives to incarceration are  
38 “opioid intervention court,” “opiate treatment court,” “heroin court,” “treatment pathway

1 program,” “overdose avoidance and recovery program,” and “heroin overdose prevention and  
2 education initiative.”<sup>5</sup> The U.S. Department of Justice (DOJ) broadly describes these programs as  
3 “pretrial diversion programs” to which the U.S. Attorney has discretion to “divert” if there are  
4 “substance abuse or mental health challenges.”<sup>6</sup>

5  
6 Given the many different types of programs that are designed to provide mental health or SUD  
7 services as an alternative to incarceration, for the purposes of this report, any program that  
8 addresses substance use or mental health in a justice-involved or justice-related setting or program  
9 will be denoted as a “diversion program.” A recent issue brief from the National Conference of  
10 State Legislatures (NCSL)<sup>7</sup> further explains that “Pretrial diversion programs are post-arrest  
11 interventions that occur at some point prior to final entry of judgment. Programs can take place  
12 before charges are filed, before first appearance or before adjudication.”

13  
14 Public health and public justice and law enforcement officials generally agree on the considerable  
15 need to treat mental illness and SUDs. Data reported by the U.S. Substance Abuse and Mental  
16 Health Services Administration (SAMHSA) show much greater prevalence of mental illness and  
17 SUDs in jails and prisons compared to the general population. It is estimated that:<sup>8</sup>

- 18
- 19 • 18 percent of the general population has a mental illness; 44 percent of those in jail and  
20 37 percent of those in prison have a mental illness;
- 21 • 11 percent of 18–25-year-olds, and 6 percent of those over 25 years old have a SUD; and
- 22 • 63 percent of people in jail and 58 percent in prison have a SUD.

23  
24 In terms of sheer numbers, “1.2 million individuals living with mental illness sit in jail and prison  
25 each year.”<sup>9</sup> Making matters more challenging, more than 60 percent of individuals with a history  
26 of mental illness do not receive treatment while incarcerated, and more than 50 percent of  
27 individuals receiving medication for mental health conditions stop taking them upon being  
28 incarcerated.<sup>10</sup> The National Institutes on Drug Abuse says that estimates for SUD prevalence in  
29 jails and prisons have been as high as 65 percent.<sup>11</sup>

## 30 31 DISCUSSION

### 32 33 *Are Diversion Programs an Effective Method of Intervention for Individuals with Mental Illness or* 34 *Substance Use Disorder Involved with the Justice System?*

35  
36 The first issue to address is whether diversion programs are an effective method of intervention for  
37 individuals with a mental illness or SUD involved with the justice system. If so, what elements of a  
38 diversion program demonstrate efficacy? For the purposes of this report, at least two metrics for  
39 “efficacy” can be viewed as to whether individuals receive and continue to engage in treatment, as  
40 well as whether they become re-incarcerated. While it is beyond the scope of this report to evaluate  
41 the 4,000+ programs in existence in the United States, there are innumerable examples of programs  
42 reporting that individuals enrolled in diversion programs not only start and continue treatment but  
43 are also less likely to return to jail or prison or be re-arrested. Proponents of diversion programs  
44 cite multiple economic and other benefits, including that they can connect hundreds of thousands of  
45 individuals to medications for opioid use disorder (OUD).

46  
47 A sample of meta-analyses also show general positivity, but identify challenges that come with  
48 evaluating such programs:

- 1 • A 2012 meta-analysis found that adult drug courts are effective “in reducing  
2 recidivism...[and] The evidence assessing DWI courts’ effectiveness is very promising but  
3 more experimental evaluations are needed. Juvenile drug courts typically produce small  
4 reductions in recidivism.”<sup>12</sup>
- 5 • A 2013 meta-review broadly found benefits of juvenile justice diversion programs.<sup>13</sup>
- 6 • A 2016 review of juvenile justice programs found, “There is no evidence that juvenile drug  
7 courts are more or less effective than traditional court processing in terms of reducing  
8 juveniles’ recidivism and drug use, but there is also no evidence of harm. The quality of  
9 the body of evidence is very low, however, so we have little confidence in these null  
10 findings.”<sup>14</sup>
- 11 • A 2016 guide from the National Drug Court Institute cited multiple studies showing that,  
12 “Use of all three [MOUD] medications is associated with significantly reduced use of  
13 unauthorized opioids among probationers, parolees, and other persons with opioid use  
14 disorders involved in the criminal justice system.”<sup>15</sup>
- 15 • A 2017 review of mental health courts (MHC) found that, “Overall, a small effect of MHC  
16 participation on recidivism was noted, compared with traditional criminal processing.  
17 Findings suggest the need for research to identify additional sources of variability in the  
18 effectiveness of MHCs.”<sup>16</sup>
- 19 • A 2019 systematic review of drug courts found that, “Treatment accessed via community-  
20 based diversion is effective at reducing drug use in Class A drug-using offenders. Evidence  
21 of a reduction in offending amongst this group as a result of diversion is uncertain. Poor  
22 methodological quality and data largely limited to US methamphetamine users limits  
23 available evidence.”<sup>17</sup>
- 24 • A 2020 literature review of mental health courts found that, while research generally  
25 supports MHCs’ positive effects to reduce recidivism, there are inconsistencies with  
26 overall study designs, data collection, lack of adequate controls and other methodological  
27 faults.<sup>18</sup>
- 28 • Another 2020 meta-analysis found that, “diversion programs for low-level drug offenders  
29 are likely to be cost-effective, generating savings in the criminal justice system while only  
30 moderately increasing healthcare costs. Such programs can reduce incarceration and its  
31 associated costs and avert overdose deaths and improve quality of life for PWID [people  
32 who inject drugs], PWUD [people who use drugs], and the broader population (through  
33 reduced HIV and HCV transmission).”<sup>19</sup>

34  
35 Considering individual programs reporting broad benefits<sup>20</sup> and meta-analyses showing benefits as  
36 well as raising questions about how broad those benefits might be, it seems prudent to call for  
37 additional research as well as mechanisms to identify best practices. For example, some programs  
38 to treat OUD might prohibit use of medications for opioid use disorder (MOUD) or rely on non-  
39 evidence-based approaches. The Board of Trustees notes, however, that what works in one  
40 jurisdiction may not work in another—and given the evidence that points to the overall benefits and  
41 lack of harm, we believe that the AMA should continue to support these programs. To guide  
42 programs, we highlight that professional medical organizations have published multiple guidelines  
43 and treatment considerations for diversion programs and care for individuals involved with the  
44 justice system, including the American Society of Addiction Medicine,<sup>21</sup> American Psychiatric  
45 Association,<sup>22</sup> and Providers Clinical Support System.<sup>23</sup>

46  
47 There are many potential elements of “a comprehensive system of community-based supports and  
48 services.” This includes benefits provided by “wraparound services,” such as community-based  
49 interagency cooperation, care coordination, child and/or family teams, unified plans of care,  
50 evidence-based systems of care, and other areas.<sup>24</sup> Additional guidance can be found in recent

1 SAMHSA grants for diversion programs in three jurisdictions.<sup>25</sup> These grants identify multiple  
2 types of services that may be useful in a diversion program, including motivational interviewing;  
3 crisis intervention training; psychiatric/psychosocial rehabilitation; dialectical behavior therapy;  
4 community-based treatment; case management; comprehensive psychiatric services, including  
5 psychotherapy and supportive counseling; substance use and detoxification treatment; housing and  
6 employment support, including skills training; screening, assessment, referral, and treatment to  
7 individuals at risk of entering the criminal justice system; and links between individuals and other  
8 community resources. While not all diversion programs will have all these elements, the Board of  
9 Trustees believes that the AMA should support development of diversion programs that include  
10 broad-based community support that include these types of resources.

11  
12 *Should Diversion Programs be Available to Both Nonviolent and Violent Offenders?*

13  
14 The second issue is whether diversion programs should be available to both nonviolent and violent  
15 offenders. It is first important to distinguish that *access to a diversion program* is related to—but  
16 different from than *access to evidence-based treatment* for a mental illness or SUD within the  
17 justice system. In 2022, the DOJ issued guidance making it clear that the Americans with  
18 Disabilities Act (ADA) protects individuals with an OUD to continue treatment for an OUD while  
19 incarcerated, including protecting continuity of care with MOUD.<sup>26</sup> The AMA has advocated in  
20 multiple legal, legislative, and other forums that individuals involved with the justice system have a  
21 medical—and constitutional right—to continue OUD while incarcerated. This advocacy is  
22 highlighted in seminal cases: *Smith v. Aroostook County*<sup>27</sup> and *Pesce v. Coppinger*.<sup>28</sup> By extension,  
23 an individual also likely has statutory and constitutional rights to MOUD—or other evidence-based  
24 care—in a diversion program, but as the DOJ points out, there may be nuances if “the individual is  
25 currently engaged in illegal drug use.”<sup>29</sup> The National Institute on Drug Abuse (NIDA) explains  
26 that:

27  
28       The chronic nature of addiction means that for some people relapse, or a return to  
29       drug use after an attempt to stop, can be part of the process, but newer treatments  
30       are designed to help with relapse prevention. Relapse rates for drug use are similar  
31       to rates for other chronic medical illnesses. If people stop following their medical  
32       treatment plan, they are likely to relapse.<sup>30</sup>

33  
34 The Board of Trustees believes that AMA support for individuals being able to stay in treatment  
35 even if they engaged in illegal drug use is a natural extension of existing AMA policy to not punish  
36 people because they have a SUD.

37  
38 With respect to whether diversion programs should be available to non-violent and violent  
39 offenders, given the evidence showing benefits of these programs—even if limited in some cases—  
40 the AMA should continue to support access to evidence-based care, including MOUD, for non-  
41 violent offenders. Notably, no change in policy is needed to meet this result. Whether to support  
42 and advocate for diversion programs to be available to individuals charged or convicted of violent  
43 offenses, however, raises multiple issues.

44  
45 The first issue is whether those charged or convicted of a violent offense are legally eligible for a  
46 diversion program. The U.S. Government Accountability Office (GAO) reports that, “adult drug  
47 courts funded by DOJ grants are prohibited by law from using grant funding to include individuals  
48 with prior or current violent offenses in their programs.”<sup>31</sup> The GAO pointed out, however, that, “a  
49 few adult drug courts told us that they admit violent offenders, by ensuring that they do not use  
50 federal funding to serve these clients.” The GAO, which interviewed representatives from 44 adult  
51 drug courts from a mix of rural, suburban, urban, and tribal adult drug courts, highlighted that some

1 violent offenders and those convicted of drug-related crimes would benefit from drug court  
2 services. State law also commonly excludes individuals charged or convicted of a violent offense—  
3 or having been convicted within a certain time period in the past.

4  
5 The National Association of Drug Court Professionals counsels that, “Evidence does not support  
6 blanket disqualification from treatment court for persons with a history of violent crimes. Instead,  
7 persons charged with offenses involving violence, or who have a history of such offenses, should  
8 be evaluated on a case-by-case basis to determine if they can be safely supervised in treatment  
9 court.”<sup>32</sup> The Board of Trustees agrees. Just as AMA policy does not discriminate against an  
10 individual’s right to receive treatment based on external factors, the AMA should not discriminate  
11 against access to evidence-based care for SUD and mental illness based on carceral status or  
12 judicial supervision. As noted above, the provision of evidence-based care for mental illness and  
13 SUDs has strong constitutional protections. And as discussed below, current AMA policy strongly  
14 supports evidence-based care for individuals with a mental illness or SUD in jails and prisons.

15  
16 Saying that the AMA should not oppose participation in a diversion program does not mean,  
17 however, that there should not be comprehensive considerations about which individuals would  
18 benefit most from participation in a diversion program. Such considerations, moreover, should  
19 include whether an individual’s participation constitutes a threat to public safety. Thankfully, there  
20 are robust eligibility criteria to help judicial and health care professionals make those  
21 determinations. This guidance can help ensure “equitable access, services, and outcomes for all  
22 sociodemographic and sociocultural groups,” including “guidance for treatment courts to monitor  
23 and rectify unwarranted cultural disparities.”<sup>33</sup> The eligibility guidance, moreover, can help  
24 diversion programs remove inappropriate restrictions and exclusions, ensure evidence-based care,  
25 connect individuals to complementary services, as well as avoid conflicts of interest. And just as  
26 important, the Board of Trustees agrees that:

27  
28 All persons meeting evidence-based eligibility criteria for treatment court receive  
29 the same opportunity to participate and succeed in the program regardless of their  
30 sociodemographic characteristics or sociocultural identity, including but not  
31 limited to their race, ethnicity, sex, gender identity, sexual orientation, age,  
32 socioeconomic status, national origin, native language, religion, cultural practices,  
33 and physical, medical, or other conditions.<sup>34</sup>

#### 34 35 AMA POLICY

36  
37 A bedrock of AMA advocacy is found in Policy H-430-987, “Medications for Opioid Use Disorder  
38 in Correctional Facilities,” which provides, “Our AMA endorses: (a) the medical treatment model  
39 of employing medications for opioid use disorder (OUD) as the standard of care for persons with  
40 OUD who are incarcerated.” This policy also calls for the AMA to advocate for

41  
42 . . . legislation, standards, policies, and funding that require correctional facilities  
43 to increase access to evidence-based treatment of OUD, including initiation and  
44 continuation of medications for OUD, in conjunction with psychosocial treatment  
45 when desired by the person with OUD, in correctional facilities within the United  
46 States and that this apply to all individuals who are incarcerated, including  
47 individuals who are pregnant, postpartum, or parenting.

1 The Board of Trustees recommends that diversion programs be held to the same standards.

2  
3 The AMA also supports “veterans courts” as “a method of intervention for veterans who commit  
4 criminal offenses that may be related to a neurological or psychiatric disorder.” (Policy H-510-979,  
5 “Support for Veterans Courts”). If AMA policy supports broad access to veterans’ courts as a  
6 matter of policy, the Board of Trustees does not see any reason why such policy should not also  
7 apply to other types of diversion programs. Similarly, AMA policy calling to support “justice  
8 reinvestment initiatives ... and assessing individuals for substance use disorders and mental health  
9 issues, expanding jail diversion and jail alternative programs, and increasing access to reentry and  
10 treatment programs,” does not distinguish between nonviolent and violent offenses.  
11 (Policy H-94-931, “AMA Support for Justice Reinvestment Initiatives”).  
12

13 Finally, AMA Ethics Policy recognizes that, “Although convicted criminals have fewer rights and  
14 protections than other citizens, being convicted of a crime does not deprive an offender of all  
15 protections under the law.” (Policy E-9.7.2, “Court-Initiated Medical Treatment in Criminal  
16 Cases”). This policy also counsels for physicians to, “Treat patients based on sound medical  
17 diagnoses, not court-defined behaviors. While a court has the authority to identify criminal  
18 behavior, a court does not have the ability to make a medical diagnosis or to determine the type of  
19 treatment that will be administered.” (Policy E-9.7.2, “Court-Initiated Medical Treatment in  
20 Criminal Cases”). Thus, while the justice system may have guidance about which individuals are  
21 eligible for a diversion program, the physician’s role is not to raise barriers to such care.  
22

## 23 RECOMMENDATIONS

24  
25 The Board of Trustees recommends that existing policy – Policy H-100.955, entitled, “Support for  
26 Drug Courts” – be amended by addition and deletion in lieu of Resolution 202 as follows:  
27

### 28 Support for Diversion Programs, Including Drug Courts, Mental Health Courts, Veterans 29 Courts, Sobriety Courts, and Similar Programs

30  
31 Our AMA:

32  
33 (1) supports the establishment and use of diversion and treatment programs ~~drug~~  
34 ~~courts, including drug courts, mental health courts, veterans courts, sobriety courts,~~  
35 and other types of similar programs, as an effective method of intervention within a  
36 comprehensive system of community-based supports and services for individuals  
37 with a mental illness or substance use disorder involved in the justice system  
38 ~~addictive disease who are convicted of nonviolent crimes;~~

39 (2) encourages legislators and court systems to establish diversion and treatment  
40 programs ~~drug courts~~ at the state and local level in the United States; ~~and~~

41 (3) encourages diversion and treatment programs ~~drug courts~~ to rely upon evidence-based  
42 models of care, including medications for opioid use disorder, for those who the judge or  
43 court determine would benefit from intervention, including treatment, rather than  
44 incarceration; and

45 (4) supports individuals enrolled in diversion or treatment programs not be removed from a  
46 program solely because of evidence showing that an individual used illegal drugs while  
47 enrolled. (Modify HOD Policy)

Fiscal Note: Less than \$500.

## REFERENCES

- <sup>1</sup> All Rise, formerly known as the National Association of Drug Court Professionals. <https://allrise.org/about/treatment-courts/>
- <sup>2</sup> Pretrial Diversion. National Conference of State Legislatures. September 2017. Available at <https://www.ncsl.org/civil-and-criminal-justice/pretrial-diversion>
- <sup>3</sup> Drug Courts: A Smart Approach to Criminal Justice. Office of National Drug Control Policy. May 2011. Available at [https://obamawhitehouse.archives.gov/sites/default/files/ondcp/Fact\\_Sheets/drug\\_courts\\_fact\\_sheet\\_5-31-11.pdf](https://obamawhitehouse.archives.gov/sites/default/files/ondcp/Fact_Sheets/drug_courts_fact_sheet_5-31-11.pdf)
- <sup>4</sup> See, for example, letter from AMA Executive Vice President and CEO, James L. Madara, MD, to the National Governors Association, American Medical Association comments on “Reducing Prescription Drug Abuse: Lessons Learned, from an NGA Policy Academy.” December 17, 2013. Available at <https://searchlf.ama-assn.org/letter/documentDownload?uri=%2Funstructured%2Fbinary%2Fletter%2FLETTERS%2Fnga-recommendations-lessons-learned.pdf>
- <sup>5</sup> Lucas, David; Arnold, Aaron. Center for Court Innovation. July 2019. Available at [https://www.cossup.org/Content/Documents/Articles/Court\\_Responses\\_To\\_The\\_Opioid\\_Epidemic\\_Happening\\_Now.pdf](https://www.cossup.org/Content/Documents/Articles/Court_Responses_To_The_Opioid_Epidemic_Happening_Now.pdf)
- <sup>6</sup> “Pretrial Diversion Program.” Justice Manual. Title 9. U.S. Department of Justice. Updated February 2023. Available at <https://www.justice.gov/jm/jm-9-22000-pretrial-diversion-program>
- <sup>7</sup> The Legislative Primer Series for Front-End Justice: Deflection and Diversion. National Conference of State Legislatures. August 2023. Available at <https://documents.ncsl.org/wwwncsl/Criminal-Justice/Deflection-Diversion-f02.pdf>
- <sup>8</sup> About Criminal and Juvenile Justice. U.S. Substance Abuse and Mental Health Services Administration. Last Updated March 2, 2022. Available at <https://www.samhsa.gov/criminal-juvenile-justice>
- <sup>9</sup> Access to Mental Health Care and Incarceration. Mental Health America. Available at <https://www.mhanational.org/issues/access-mental-health-care-and-incarceration> Last accessed February 23, 2024
- <sup>10</sup> Mental Health Treatment While Incarcerated. National Alliance on Mental Illness. Available at <https://www.nami.org/Advocacy/Policy-Priorities/Improving-Health/Mental-Health-Treatment-While-Incarcerated>
- <sup>11</sup> Criminal Justice Drug Facts. National Institutes on Drug Abuse. Last updated June 2020. Available at <https://nida.nih.gov/publications/drugfacts/criminal-justice>
- <sup>12</sup> Ojmarh Mitchell, David B. Wilson, Amy Eggers, Doris L. MacKenzie, Assessing the effectiveness of drug courts on recidivism: A meta-analytic review of traditional and non-traditional drug courts, Journal of Criminal Justice, Volume 40, Issue 1, 2012, Pages 60-71, <https://doi.org/10.1016/j.jcrimjus.2011.11.009>. <https://www.sciencedirect.com/science/article/pii/S0047235211001255>
- <sup>13</sup> The Effect of Youth Diversion Programs on Recidivism. A Meta-Analytic Review. Criminal Justice and Behavior. Vol. 40. No. 5. May 2013. Available at [http://users.soc.umn.edu/~uggen/Wilson\\_CJB\\_13.pdf](http://users.soc.umn.edu/~uggen/Wilson_CJB_13.pdf)
- <sup>14</sup> Meta-Analysis of Research on the Effectiveness of Juvenile Drug Courts. Emily E. Tanner-Smith, PhD Mark W. Lipsey, PhD. David B. Wilson, PhD. Peabody Research Institute at Vanderbilt University. Available at <https://www.ojp.gov/pdffiles1/ojdp/grants/250439.pdf>
- <sup>15</sup> Drug Court Practitioner Fact Sheet. Medication-Assisted Treatment for Opioid Use Disorders in Drug Courts. National Drug Court Institute. August 2016. Vol. XI, No. 2. Available at [https://allrise.org/wp-content/uploads/2022/07/mat\\_fact\\_sheet-1.pdf](https://allrise.org/wp-content/uploads/2022/07/mat_fact_sheet-1.pdf)
- <sup>16</sup> Lowder EM, Rade CB, Desmarais SL. Effectiveness of Mental Health Courts in Reducing Recidivism: A Meta-Analysis. Psychiatr Serv. 2018 Jan 1;69(1):15-22. doi: 10.1176/appi.ps.201700107. Epub 2017 Aug 15. PMID: 28806894.
- <sup>17</sup> Hayhurst, K. P., Leitner, M., Davies, L., Millar, T., Jones, A., Flentje, R., Hickman, M., Fazel, S., Mayet, S., King, C., Senior, J., Lennox, C., Gold, R., Buck, D., & Shaw, J. (2019). The effectiveness of diversion programmes for offenders using Class A drugs: A systematic review and meta-analysis. Drugs: Education, Prevention & Policy, 26(2), 113–124. <https://doi.org/10.1080/09687637.2017.1398715>
- <sup>18</sup> Otto, H. D. (2020). A review of literature on mental health court goals, effectiveness, and future implications. Illinois Criminal Justice Information Authority.

<sup>19</sup> Bernard CL, Rao IJ, Robison KK, Brandeau ML. Health outcomes and cost-effectiveness of diversion programs for low-level drug offenders: A model-based analysis. *PLoS Med.* 2020 Oct 13;17(10):e1003239. doi: 10.1371/journal.pmed.1003239. PMID: 33048929; PMCID: PMC7553283.

<sup>20</sup> For example, a study supported by the U.S. Department of Justice, National Institute of Justice evaluating the Multnomah County Drug Court in Oregon showed that participating offenders were rearrested less frequently than offenders going through traditional court. Drug court participants cost local taxpayers \$5,071 less on average over a 30-month period than those processed through traditional court. Overall, the drug courts saved Multnomah County more than \$1.5 million per year or approximately \$5,000 on average for each of the program participants in the study.

<sup>21</sup> Drug Court Resources. American Society of Addiction Medicine. Available at <https://www.asam.org/quality-care/clinical-guidelines/clinical-resources/drug-court-resources>

<sup>22</sup> Examining Mental Health Courts. American Psychiatric Association. Available at <https://www.psychiatry.org/news-room/apa-blogs/examining-mental-health-courts>

<sup>23</sup> Drug Court/Treatment Court. Providers Clinical Support System. Available at <https://pcssnow.org/topics/drug-court-treatment-court/>

<sup>24</sup> “Wraparound Process.” Literature review. Washington, D.C. Office of Juvenile Justice and Delinquency Prevention. [https://www.ojjdp.gov/mpg/litreviews/Wraparound\\_Process.pdf](https://www.ojjdp.gov/mpg/litreviews/Wraparound_Process.pdf) Last updated April 2014.

<sup>25</sup> Law Enforcement and Behavioral Health Partnerships for Early Diversion. U.S. Substance Abuse and Mental Health Services Administration. Last Updated January 30, 2024. Available at <https://www.samhsa.gov/criminal-juvenile-justice/grants-grantees/early-diversion>

<sup>26</sup> The Americans with Disabilities Act and the Opioid Crisis: Combating Discrimination Against People in Treatment or Recovery. U.S. Department of Justice. Civil Rights Division. April 5, 2022. Available at [https://archive.ada.gov/opioid\\_guidance.pdf](https://archive.ada.gov/opioid_guidance.pdf)

<sup>27</sup> See, generally, *Smith v. Aroostook County*. ACLU of Maine. <https://www.aclumaine.org/en/cases/smith-v-arostook-county>

<sup>28</sup> See, generally, *Pesce v. Coppinger*. ACLU of Massachusetts. <https://www.aclum.org/en/cases/pesce-v-coppinger>

<sup>29</sup> The Americans with Disabilities Act and the Opioid Crisis: Combating Discrimination Against People in Treatment or Recovery. U.S. Department of Justice. Civil Rights Division. April 5, 2022. Available at [https://archive.ada.gov/opioid\\_guidance.pdf](https://archive.ada.gov/opioid_guidance.pdf)

<sup>30</sup> NIDA. 2023, September 25. Treatment and Recovery. Retrieved from <https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery-on-February-24-2024>.

<sup>31</sup> Factors Related to Eligibility and Acceptance of Offers to Participate in DOJ Funded Adult Drug Courts. U.S. Government Accountability Office. February 2023. Available at <https://www.gao.gov/assets/gao-23-105272.pdf>

<sup>32</sup> “Adult Treatment Court Best Practice Standards.” All Rise. 2023. [https://allrise.org/wp-content/uploads/2023/12/All-Rise-Adult-Treatment-Court-Best-Practice-Standards-2nd-Ed.-I-VI\\_final.pdf](https://allrise.org/wp-content/uploads/2023/12/All-Rise-Adult-Treatment-Court-Best-Practice-Standards-2nd-Ed.-I-VI_final.pdf)

<sup>33</sup> “Adult Treatment Court Best Practice Standards.” All Rise. 2023. [https://allrise.org/wp-content/uploads/2023/12/All-Rise-Adult-Treatment-Court-Best-Practice-Standards-2nd-Ed.-I-VI\\_final.pdf](https://allrise.org/wp-content/uploads/2023/12/All-Rise-Adult-Treatment-Court-Best-Practice-Standards-2nd-Ed.-I-VI_final.pdf)

<sup>34</sup> “Adult Treatment Court Best Practice Standards.” All Rise. 2023. [https://allrise.org/wp-content/uploads/2023/12/All-Rise-Adult-Treatment-Court-Best-Practice-Standards-2nd-Ed.-I-VI\\_final.pdf](https://allrise.org/wp-content/uploads/2023/12/All-Rise-Adult-Treatment-Court-Best-Practice-Standards-2nd-Ed.-I-VI_final.pdf)